open access

Vol 66, No 3 (2016)
Research paper (original)
Published online: 2016-07-12
Get Citation

Differences in treatment outcomes in selected cancers in Poland compared to other European countries in 2005–2009, based on CONCORD 2 study

Magdalena Bielska-Lasota, Michalina Krzyżak, Katarzyna Kwiatkowska, Joanna Bogusz, Dominik Maślach, Mirosław J. Wysocki
DOI: 10.5603/NJO.2016.0035
·
Nowotwory. Journal of Oncology 2016;66(3):202-211.

open access

Vol 66, No 3 (2016)
Original article
Published online: 2016-07-12

Abstract

Background. The 5-year net survival rates show the outcomes of cancer treatment in population, therefore, they are one of the most important measures used to evaluate the effectiveness of cancer treatment. The standardized methodology in CONCORD 2 study of global cancer survival allows to compare the net survival in Poland with other European countries. The aim of this article was to assess the treatment in selected cancers in Poland and selected Polish voivodships in comparison to other European countries.

Methods. In our analyses the CONCORD 2 results, based on the data from population-based Cancer Registries for patients diagnosed: 2005–2009 and followed up to 2009, were used. The results regarding Poland included the data previously provided by the National Cancer Registry and four Regional Cancer Registries: Greater Poland, Świętokrzyskie, Lower Silesia and Podkarpackie. The Pohar Perme’s method called net survival was used to calculate the 5-year survival.

Results. The 5-year net survival in Poland was the lowest in Europe for patients diagnosed with prostate (74%), breast (74%), colon (50%), rectum (47%), stomach (19%), ovary (34%), cervical (53%) cancers. However, the survival for patients diagnosed with leukemias (49%) and lung cancer (13%) was on the average European level. The analysis of voivodships’ data proved the differences in the regions. The highest differences were for patients with leukemias in Lower Silesia and Świętokrzyskie (14%), prostate cancer in Greater Poland and Świętokrzyskie (10%), breast cancer in Greater Poland and Podkarpackie (6%), which showed differences in prevention and treatment standards.

Conclusions. The study showed the differences in 5-year net survival rates in Europe, which were unfavourable for Poland. Cancers that have good prognosis such as: prostate, breast, colon and rectum had the lowest survival rates in Europe, however, patients with lung cancer and leukemias were on the average European level.  

Abstract

Background. The 5-year net survival rates show the outcomes of cancer treatment in population, therefore, they are one of the most important measures used to evaluate the effectiveness of cancer treatment. The standardized methodology in CONCORD 2 study of global cancer survival allows to compare the net survival in Poland with other European countries. The aim of this article was to assess the treatment in selected cancers in Poland and selected Polish voivodships in comparison to other European countries.

Methods. In our analyses the CONCORD 2 results, based on the data from population-based Cancer Registries for patients diagnosed: 2005–2009 and followed up to 2009, were used. The results regarding Poland included the data previously provided by the National Cancer Registry and four Regional Cancer Registries: Greater Poland, Świętokrzyskie, Lower Silesia and Podkarpackie. The Pohar Perme’s method called net survival was used to calculate the 5-year survival.

Results. The 5-year net survival in Poland was the lowest in Europe for patients diagnosed with prostate (74%), breast (74%), colon (50%), rectum (47%), stomach (19%), ovary (34%), cervical (53%) cancers. However, the survival for patients diagnosed with leukemias (49%) and lung cancer (13%) was on the average European level. The analysis of voivodships’ data proved the differences in the regions. The highest differences were for patients with leukemias in Lower Silesia and Świętokrzyskie (14%), prostate cancer in Greater Poland and Świętokrzyskie (10%), breast cancer in Greater Poland and Podkarpackie (6%), which showed differences in prevention and treatment standards.

Conclusions. The study showed the differences in 5-year net survival rates in Europe, which were unfavourable for Poland. Cancers that have good prognosis such as: prostate, breast, colon and rectum had the lowest survival rates in Europe, however, patients with lung cancer and leukemias were on the average European level.  

Get Citation

Keywords

cancer, 5-year net survival, CONCORD 2

About this article
Title

Differences in treatment outcomes in selected cancers in Poland compared to other European countries in 2005–2009, based on CONCORD 2 study

Journal

Nowotwory. Journal of Oncology

Issue

Vol 66, No 3 (2016)

Article type

Research paper (original)

Pages

202-211

Published online

2016-07-12

DOI

10.5603/NJO.2016.0035

Bibliographic record

Nowotwory. Journal of Oncology 2016;66(3):202-211.

Keywords

cancer
5-year net survival
CONCORD 2

Authors

Magdalena Bielska-Lasota
Michalina Krzyżak
Katarzyna Kwiatkowska
Joanna Bogusz
Dominik Maślach
Mirosław J. Wysocki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl